Denosumab: What’s New?

Bogado, César E.; Zanchetta, María Belén; Boailchuk, Juan A.; Massari, Fabio; Zanchetta, José R.

doi:10.1007/s11914-010-0040-1

Cited by 6 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be used in patients regardless of renal function level, but transient hypocalcemia is more common in patients with severe renal failure. 381 Odanacatib is part of an emerging treatment category and is a cathepsin K inhibitor that interferes with an enzyme pathway in osteoclasts important for bone resorption but does not appear to have an effect on bone formation rates. Odanacatib, given by pill once weekly, causes osteoclasts to stop resorbing bone but does not cause the osteoclast to undergo apoptosis.…”

Section: Treatment Of Osteoporosismentioning

confidence: 99%

See 1 more Smart Citation

A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2

Mears¹,

Kates²

2015

Geriatr Orthop Surg Rehabil

127

121

View full text Add to dashboard Cite

Over the past 4 decades, much has been learned about the pathophysiology and treatment of osteoporosis, the prevention of fragility fractures, and the perioperative management of patients who have these debilitating injuries. However, the volume of published literature on this topic is staggering and far too voluminous for any clinician to review and synthesize by him or herself. This manuscript thoroughly summarizes the latest research on fragility fractures and provides the reader with valuable strategies to optimize the prevention and management of these devastating injuries. The information contained in this article will prove invaluable to any health care provider or health system administrator who is involved in the prevention and management of fragility hip fractures. As providers begin to gain a better understanding of the principles espoused in this article, it is our hope that they will be able to use this information to optimize the care they provide for elderly patients who are at risk of or who have osteoporotic fractures.

show abstract

Section: Treatment Of Osteoporosismentioning

confidence: 99%

“…It can be used in patients regardless of renal function level, but transient hypocalcemia is more common in patients with severe renal failure. 381…”

Section: Osteoporosis Managementmentioning

confidence: 99%

A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2

Mears¹,

Kates²

2015

Geriatr Orthop Surg Rehabil

127

121

View full text Add to dashboard Cite

show abstract

“…Antiangiogenic medication is used mainly in the treatment of gastrointestinal, renal and neuro-endocrine malignancies [4]. The RANKL inhibitor (denosumab) is an antiresorptive agent used to treat osteoporosis or to relieve symptoms of bone metastatic disease [5,6]. Generally, bisphosphonates are well tolerated, but some adverse effects are also reported: renal toxicity, atrial fibrillation, skin and inflammatory ocular reactions, musculoskeletal pain, gastrointestinal irritation, atypical femoral fractures, and last but not least osteonecrosis of the jaw [7][8][9][10][11][12].…”

mentioning

confidence: 99%

Osteonecrosis of the Mandible Associated with Bisphosphonate Treatment

Popescu¹,

Ciofu²,

Popescu³

et al. 2017

Rev. Chim.

View full text Add to dashboard Cite

This study analyzes 35 patients with bisphosphonate-related osteonecrosis of the mandible (BRONJ) diagnosed and treated in the Oral and Maxillofacial Surgery Clinic of St. Spiridon Hospital Iasi. The inclusion criteria were in line with the recommendations of the American Association of Oral and Maxillofacial Surgery (AAOMS). The analysis included the underlying disease, the type of bisphosphonate and the route of administration, the duration of treatment as well as the osteonecrosis triggering factor. Surgery was consistent with the condition of the disease, ranging from debridement and sequestrectomy to alveolar marginal and even segmental bone resections. The results of the study were similar with the data from the literature suggesting that the condition is more common in the lower jaw compared to the upper jaw, and the main risk factors are dental extraction and intravenous bisphosphonate administration.

show abstract

“…11 Clinically, Dmab has less severe adverse effects, such as gastrointestinal tract ulceration or kidney dysfunction, when compared with BPs. 9 In the human RANKL knock-in mice model, it was demonstrated that Dmab treatment resulted in >95% reduction in serum tartrateresistant acid phosphatase (TRAP)-5b in as early as 7 days, 12 indicating that Dmab significantly inhibits the formation of mature osteoclasts in vivo.…”

mentioning

confidence: 99%

Impaired Bone Resorption and Woven Bone Formation Are Associated with Development of Osteonecrosis of the Jaw-Like Lesions by Bisphosphonate and Anti–Receptor Activator of NF-κB Ligand Antibody in Mice

Williams

Lee

Kim

et al. 2014

The American Journal of Pathology

View full text Add to dashboard Cite

Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs after dental-related interventions in patients undergoing treatment with bisphosphonates or denosumab, the neutralizing human anti-receptor activator of NF-κB ligand (RANKL) antibody (Ab). The cause of ONJ by these drugs has been speculated to their direct effects on osteoclasts. However, the extent to which osteoclasts contribute to ONJ pathogenesis remains controversial. Herein, by using a tooth-extraction mouse model with i.v. administration of mouse anti-RANKL Ab or the bisphosphonate zoledronate (ZOL), we show that unresorbed bone due to impaired formation or suppressed functions of osteoclasts, respectively, is associated with ONJ development. After tooth extraction, ONJ-like lesions developed 50% in the anti-RANKL Ab-treated mice and 30% in the ZOL-treated mice. Nonviable and unresorbed bone was found more in anti-RANKL Ab-treated mice compared with mice receiving ZOL. All mice receiving anti-RANKL Ab had an undetectable tartrate-resistant acid phosphatase (TRAP) level in the serum and no TRAP-positive osteoclasts at the extracted sockets, whereas ZOL-treated mice had a decreased TRAP level without altering the numbers of TRAP-positive osteoclasts. Interestingly, the absence of newly formed woven bone in the extracted sockets was evident in ONJ-like lesions from both anti-RANKL Ab- and ZOL-treated mice. Our study suggests that the lack of osteoclasts' bone-resorptive functions by these drugs and suppression of woven bone formation after dental trauma may be associated with ONJ development.

show abstract

Denosumab: What’s New?

Cited by 6 publications

References 25 publications

A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2

A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2

Osteonecrosis of the Mandible Associated with Bisphosphonate Treatment

Impaired Bone Resorption and Woven Bone Formation Are Associated with Development of Osteonecrosis of the Jaw-Like Lesions by Bisphosphonate and Anti–Receptor Activator of NF-κB Ligand Antibody in Mice

Contact Info

Product

Resources

About